FGFR3 and urinary bladder cancer: Within the complex landscape of bladder cancer, genomic analysis has revealed that about 80% of early-stage bladder cancers exhibit frequent alterations in fibroblast growth factor receptor 3 (FGFR3) that lead to both over-expression and constitutive activation, even in the absence of its natural ligand (4, 5).